Inclusion Criteria

• Only female patients are eligible.
• Patients must be 45 years of age or older.
• Patients must have signs of skin aging on face (wrinkles, rough texture, skin atrophy and skin laxity) and hands (loss of fat tissue and visibility of veins and tendons).
• Patients must have been on stable birth control for the past 6 months if able to conceive
• Patients are able and willing to provide written informed consent after the study is fully explained.

Exclusion Criteria

• Patients with clinically abnormal platelet count]\, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator.
• Patients who have had any cosmetic procedures meant to address skin aging of face and hands 3 months prior to enrollment.
• Patients who have had resurfacing laser on face or hands within one year prior to enrollment.
• Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.
• Patients who are pregnant or currently breast-feeding.
• Patients with systemic, rheumatic, or inflammatory disease or who are immunosuppressed.
• Patients with ongoing infectious disease, including HIV and hepatitis.
• Patients with history of significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes.
• Patients participating in a study of an experimental drug or medical device within 30 days of study entry.
• Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer.
• Patients taking anti-aggregating therapy.
• Patients on anticoagulant therapy.
• Patients with history of keloid formation.
• Patients with uncontrolled diabetes.
• Patients with active skin disease or skin infection on the intended treatment areas, at baseline.